Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.


Journal

Blood cancer discovery
ISSN: 2643-3249
Titre abrégé: Blood Cancer Discov
Pays: United States
ID NLM: 101764786

Informations de publication

Date de publication:
01 2022
Historique:
received: 02 06 2021
revised: 29 07 2021
accepted: 01 11 2021
entrez: 12 1 2022
pubmed: 13 1 2022
medline: 6 5 2022
Statut: ppublish

Résumé

We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (

Identifiants

pubmed: 35019853
pii: 2643-3230.BCD-21-0095
doi: 10.1158/2643-3230.BCD-21-0095
pmc: PMC9924295
doi:

Substances chimiques

Antigens, CD19 0
Receptors, Antigen, T-Cell 0
tisagenlecleucel Q6C9WHR03O

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

66-81

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007950
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

BMC Cancer. 2020 Jun 30;20(1):612
pubmed: 32605647
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Blood. 2018 Mar 22;131(12):1350-1359
pubmed: 29284596
Blood. 2012 Dec 20;120(26):5173-80
pubmed: 23074282
J Clin Oncol. 2015 Apr 10;33(11):1275-84
pubmed: 25605857
Blood. 2014 Mar 27;123(13):2017-25
pubmed: 24497539
J Clin Oncol. 2008 Jun 20;26(18):3046-50
pubmed: 18565891
Leukemia. 2021 Dec;35(12):3383-3393
pubmed: 34002027
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Leukemia. 2018 Nov;32(11):2316-2325
pubmed: 29728694
J Clin Oncol. 2021 Mar 10;39(8):920-930
pubmed: 33417474
Blood Adv. 2020 May 26;4(10):2325-2338
pubmed: 32453841
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Clin Cancer Res. 2018 Dec 15;24(24):6175-6184
pubmed: 30190371
Blood. 2019 Apr 11;133(15):1652-1663
pubmed: 30728140
Blood Adv. 2019 Nov 12;3(21):3393-3405
pubmed: 31714961
Blood. 2010 Apr 22;115(16):3206-14
pubmed: 20154213
Nat Med. 2018 Oct;24(10):1504-1506
pubmed: 30275569
J Clin Oncol. 2021 May 20;39(15):1650-1659
pubmed: 33764809
Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S71-4
pubmed: 18545248
Blood. 2015 Aug 20;126(8):964-71
pubmed: 26124497
Blood. 2015 May 28;125(22):3501-8
pubmed: 25862561
J Clin Oncol. 2009 Jan 20;27(3):377-84
pubmed: 19064980

Auteurs

Michael A Pulsipher (MA)

Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California. michael.pulsipher@hci.utah.edu.

Xia Han (X)

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Shannon L Maude (SL)

Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Theodore W Laetsch (TW)

Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas.

Muna Qayed (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Aflac Cancer and Blood Disorders Center, Healthcare of Atlanta, Atlanta, Georgia.

Susana Rives (S)

Pediatric Hematology, Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain.

Michael W Boyer (MW)

Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah.

Hidefumi Hiramatsu (H)

Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan.

Gregory A Yanik (GA)

Michigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children's Hospital, Ann Arbor, Michigan.

Tim Driscoll (T)

Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina.

G Doug Myers (GD)

Pediatric Hematology and Oncology, Children's Mercy Hospital; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.

Peter Bader (P)

Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany.

Andre Baruchel (A)

Pediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré (APHP), Paris, France.
Université de Paris et Institut de Recherche Saint-Louis (EA3518), Paris, France.

Jochen Buechner (J)

Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.

Heather E Stefanski (HE)

Department of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota.

Creton Kalfoglou (C)

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Kevin Nguyen (K)

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Edward R Waldron (ER)

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Karen Thudium Mueller (K)

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Harald J Maier (HJ)

Novartis Pharmaceuticals Corporation, Basel, Switzerland.

Gabor Kari (G)

Novartis Pharmaceuticals Corporation, Basel, Switzerland.

Stephan A Grupp (SA)

Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH